Integra LifeSciences (NASDAQ:IART – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.
Risk and Volatility
Integra LifeSciences has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500.
Profitability
This table compares Integra LifeSciences and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integra LifeSciences | -30.15% | 17.42% | 5.00% |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
Institutional & Insider Ownership
Analyst Ratings
This is a breakdown of current recommendations for Integra LifeSciences and Sight Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integra LifeSciences | 2 | 4 | 1 | 0 | 1.86 |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
Integra LifeSciences currently has a consensus target price of $18.33, indicating a potential downside of 7.36%. Sight Sciences has a consensus target price of $8.25, indicating a potential upside of 68.02%. Given Sight Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Sight Sciences is more favorable than Integra LifeSciences.
Valuation and Earnings
This table compares Integra LifeSciences and Sight Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integra LifeSciences | $1.64 billion | 0.94 | -$516.47 million | ($6.46) | -3.06 |
| Sight Sciences | $77.36 million | 3.45 | -$38.43 million | ($0.71) | -6.92 |
Sight Sciences has lower revenue, but higher earnings than Integra LifeSciences. Sight Sciences is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Sight Sciences beats Integra LifeSciences on 8 of the 14 factors compared between the two stocks.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
